Cocrystal Pharma, Inc. (COCP): Price and Financial Metrics
COCP Price/Volume Stats
Current price | $1.92 | 52-week high | $3.26 |
Prev. close | $2.22 | 52-week low | $1.33 |
Day low | $1.70 | Volume | 87,665 |
Day high | $2.29 | Avg. volume | 35,488 |
50-day MA | $2.12 | Dividend yield | N/A |
200-day MA | $2.02 | Market Cap | 19.53M |
COCP Stock Price Chart Interactive Chart >
Cocrystal Pharma, Inc. (COCP) Company Bio
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
COCP Price Returns
1-mo | -7.53% |
3-mo | -12.73% |
6-mo | 5.49% |
1-year | 22.29% |
3-year | -71.17% |
5-year | -69.81% |
YTD | -4.95% |
2024 | 17.29% |
2023 | -11.68% |
2022 | -75.00% |
2021 | -52.21% |
2020 | 174.47% |
Continue Researching COCP
Here are a few links from around the web to help you further your research on Cocrystal Pharma Inc's stock as an investment opportunity:Cocrystal Pharma Inc (COCP) Stock Price | Nasdaq
Cocrystal Pharma Inc (COCP) Stock Quote, History and News - Yahoo Finance
Cocrystal Pharma Inc (COCP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...